MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1001/jamanetworkopen.2026.23522

Медицинская библиотека · JAMA network open · 2026

Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer.

Tan Harold Nathan, Stephen Bettzy, Mirallas Oriol, Derbala Mohamed H, Salih Israa, Castillo Lilibeth, Yang Yali, Le Hung, Kang Lei, Lin Heather, Lim Joann, Dumbrava Ecaterina E, Yap Timothy A, Rodón Jordi, Piha-Paul Sarina A, Fu Siqing, Champiat Stéphane, Akhave Neal, Ferrarotto Renata, Hong David S, Meric-Bernstam Funda, Johnson Faye, Naing Aung

СтатьяПеревод в очереди

Аннотация

IMPORTANCE

Immune checkpoint inhibitors (ICIs) have transformed the management of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), yet most patients eventually develop resistance. Investigational immunotherapy strategies beyond checkpoint blockade are being explored, but their clinical activity and associated biomarkers remain poorly defined.

OBJECTIVE

To evaluate the safety, antitumor activity, and biomarkers associated with novel immunotherapy agents in patients with recurrent or metastatic HNSCC treated in early-phase clinical trials.

DESIGN, SETTING, AND

PARTICIPANTS

This retrospective cohort study was conducted at The University of Texas MD Anderson Cancer Center Department of Investigational Cancer Therapeutics and included adult patients (aged ≥18 years) with advanced HNSCC treated with novel immunotherapy agents in early-phase clinical trials between January 1, 2015, and May 31, 2025. Patients were followed up from treatment initiation until disease progression, death, or last clinical contact.

EXPOSURE: Treatment with investigational immunotherapy agents administered in early-phase clinical trials.

MAIN OUTCOMES AND MEASURES: The primary outcomes included treatment-related adverse events, objective response rate (complete or partial response), clinical benefit rate (complete or partial response or stable disease lasting ≥6 months), progression-free survival, and overall survival. Logistic regression was used to evaluate biomarkers associated with the clinical benefit rate, including clinical, genomic, and treatment-related variables, while survival outcomes were estimated using the Kaplan-Meier method.

RESULTS

The sample included 158 patients (median [range] age, 60.7 [25.7-84.6] years; 136 male [86.1%]). The oropharynx was the most common primary site (94 patients [59.6%]). Patients had received a median of 3 prior lines (range, 0-8 prior lines) of systemic therapies, and 126 patients (79.7%) had prior ICI exposure. A total of 91 of 153 patients (59.5%) had human papillomavirus-positive tumors, and PD-L1 combined positive score of at least 1 was observed in 67 of 87 patients (77.0%). Most patients received combination immunotherapy (106 [67.1%]), with a median treatment duration of 2.3 months (range, 0.1-19.7 months). Treatment-related adverse effects occurred in 85 patients (53.8%), including grade 3 or higher events in 23 patients (14.6%). The overall response rate was 7.7% (12 patients), and the clinical benefit rate was 16.1% (25 patients). Bispecific antibodies were associated with improved clinical benefit (odds ratio, 1.95; 95% CI, 1.23-4.15), whereas PIK3CA alterations were associated with reduced benefit (odds ratio, 0.03; 95% CI, 0.00-0.51). Median progression-free survival was 2.3 months (95% CI, 2.0-2.9 months) and median overall survival was 8.3 months (95% CI, 7.2-11.0 months).

CONCLUSIONS AND RELEVANCE: This retrospective cohort study of heavily pretreated patients with HNSCC treated in early-phase clinical trials found that novel immunotherapy agents may have manageable toxic effects but modest antitumor activity. Bispecific antibodies may have encouraging activity while genomic alterations may help inform treatment stratification.

Для цитирования: Tan Harold Nathan, Stephen Bettzy, Mirallas Oriol, Derbala Mohamed H, Salih Israa, Castillo Lilibeth, Yang Yali, Le Hung, Kang Lei, Lin Heather, Lim Joann, Dumbrava Ecaterina E, Yap Timothy A, Rodón Jordi, Piha-Paul Sarina A, Fu Siqing, Champiat Stéphane, Akhave Neal, Ferrarotto Renata, Hong David S, Meric-Bernstam Funda, Johnson Faye, Naing Aung. Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer.. JAMA network open. 2026. DOI: 10.1001/jamanetworkopen.2026.23522.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.